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Abstract Filaggrin (FLG) plays an important role in the barrier function of the skin. 
Several loss-of-function mutations in FLG have been identified in patients with 
ichthyosis vulgaris, and these null mutations are associated with development of atopic 
dermatitis (AD). In the present study, we examined tag single nucleotide 
polymorphisms (SNPs) and null mutations in FLG for possible associations with AD 
and atopic phenotypes in a Japanese population. Transmission disequilibrium test of 
105 AD families showed that the null allele of the S2554X variant of FLG tended to be 
overtransmitted to AD-affected offspring; however the P value did not reach statistical 
significance. In a case-control comparison of 376 AD cases and 923 non-allergic 
controls, the null allele of S2554X was significantly associated with AD (P = 0.0012), 
and the association was strengthened in subjects with AD alone (P = 0.000024). 
3321delA and S2554X were also associated with elevated levels of IgE. Combined null 
mutation carriers were observed more in AD patients and in the subjects with high IgE 
than in control subjects. The combined P value for the family and case-control data 
was significant for the S2554X and combined null mutations. Our data further support 
the importance of FLG in the development of AD.  
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Introduction  
Atopic dermatitis (AD) is an itchy, chronic inflammatory skin disease that is 
categorized as an atopic disease along with atopic asthma and rhinitis. The prevalence 
of AD has been studied in a wide variety of populations, and its reported frequency 
ranged from 0.73% to 23% (Levy et al. 2003). The 12-month prevalence of symptoms 
of atopic eczema in Japanese children 6 to 7 years of age was 16.9%, the second highest 
after Sweden (Williams et al. 1999). Twin and family studies have indicated that 
predisposition for AD is highly heritable (Larsen et al. 1986), with a heritability value 
of 0.72 (Nystad et al. 2005). However, the detailes regarding inheritance of AD remain 
unclear.  
To identify susceptibility genes for AD, genome-wide linkage studies and 
candidate gene approaches have been used. To date, 5 genome-wide linkage studies 
have been performed in Caucasian populations (Lee et al. 2000; Cookson et al. 2001; 
Bradley et al. 2002; Haagerup et al. 2004) and a Japanese population (Enomoto et al. 
2007), and evidence for linkage to AD was obtained for several chromosomal regions. 
Several candidate genes, mainly immune-related genes including interleukin (IL)-4 
(IL4), IL13, IL5, IL12B, and serine protease inhibitor Kazal-type 5 (SPINK5 ) have 
been examined for possible association with development of AD (Morar et al. 2006). 
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Recent studies have emphasized the importance of skin barrier function in the 
development of AD. Loss-of-function mutations in the filaggrin gene (FLG) were found 
to be associated with AD in independent populations (Irvine 2007). FLG protein is 
present in the granular layers of the epidermis, and the keratohyalin granules in the 
granular layers are predominantly composed of the 400-kDa polyprotein, profilagglin 
(Dale et al. 1985; Listwan and Rothnagel 2004; Candi et al. 2005). On the 
differentiation of keratinocytes, profilaggrin is dephosphorylated and cleaved into 10 to 
12 essentially identical 37-kDa filaggrin peptides. FLG proteins aggregate the keratin 
cytoskeleton system to form a dense protein-lipid matrix that is crosslinked by 
transglutaminases to form the cornified cell envelope (Candi et al. 2005). This structure 
prevents epidermal water loss and impedes the entry of allergens, toxic chemicals, and 
infectious organisms. Therefore, FLG is a key protein in terminal differentiation of the 
epidermis and skin barrier function (Gan et al. 1990).  
FLG is located on human chromosome 1q21 (Compton et al. 2002) for 
which a previous genome-wide linkage study found evidence of linkage with AD 
(Cookson et al. 2001). The chromosome 1q21 region harbors the epidermal 
differentiation complex (EDC), which is a dense cluster of genes involved in the 
terminal differentiation of the epidermis and formation of the stratum corneum, the 
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outermost dead cell compartment of the skin where the main skin barrier function 
occurs (Mischke et al. 1996). FLG is located in the EDC. Recently, we performed a 
genome-wide linkage analysis of Japanese families with AD and found weak evidence 
for linkage on 1q24 (Enomoto et al. 2007) near 1q21.  
FLG was initially identified as a susceptibility gene for ichthyosis vulgaris 
(Smith et al. 2006), a disorder of keratinization, and Palmer et al. (Palmer et al. 2006) 
reported that two nonsense mutations in FLG, R501X and 2282del4, were associated 
with development of AD in a Caucasian population. These mutations showed a 
combined allele frequency of ~4% in populations of European ancestry, and the variants 
were greatly overrepresented in the cohort with AD, indicating a highly significant 
dominant risk of AD (Palmer et al. 2006). FLG null alleles, X501 and 2282del4, occur 
at higher frequency in individuals with both asthma and AD than in individuals with 
asthma alone (Palmer et al. 2006). The R501X and 2282del4 variants were absent in 
non-European populations, such as those of Asian or African origin.  
The associations of FLG null alleles with development of AD have been 
replicated in several European populations (Marenholz et al. 2006; Ruether et al. 2006; 
Sandilands et al. 2006; Weidinger et al. 2006; Barker et al. 2007; Stemmler et al. 2007; 
Weidinger et al. 2007). FLG null alleles were also found to be associated with elevated 
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levels of IgE (Weidinger et al. 2006; Weidinger et al. 2007), and allergic sensitization 
(Weidinger et al. 2006), and Marenholz et al. (Marenholz et al. 2006) reported that 
these mutations predispose carriers to asthma, allergic rhinitis, and allergic 
sensitization only in the presence of AD. Other FLG null mutations have also been 
found to be associated with AD in a Caucasian population (Sandilands et al. 2007). In 
Japanese population, the 3321delA and S2554X mutations were associated with 
ichthyosis vulgaris and AD (Nomura et al. 2007). Most of the previous studies related 
to FLG mutations were conducted with European populations, and studies of FLG 
variants other than the null mutations in relation with AD have not been conducted. 
In the present study, we examined tag single nucleotide polymorphisms 
(SNPs) and null mutations in FLG for possible associations with AD and atopic 
phenotypes in a Japanese population.  
 
Materials and methods  
Subjects  
Probands in the AD families were patients with AD who visited the Dermatology 
Department of the University Hospital of Tsukuba (Japan) and dermatology 
departments of several hospitals in Ibaraki, Japan. AD was diagnosed in subjects 
 8
according to the criteria of Hanifin and Rajka (Hanifin and Rajka 1980). All patients 
had pruritus, typical appearance of AD, and a tendency toward chronic or chronically 
relapsing dermatitis. A full verbal and written explanation of the study was given to all 
family members interviewed, and 105 families (381 members) gave informed consent 
and participated in this study. The mean age of the probands and their siblings was 13.3 
years (range, 0.9 to 42 years). For a case-control study, 376 independent AD patients 
(ages 16-64 years, mean 29.7 years) were recruited. Control subjects for the 
case-control study were 923 healthy adults (ages 19-78 years, mean 46.2 years) with no 
history of any allergic disease. A full verbal and written explanation of the study was 
given to patients and all family members interviewed, and all provided informed 
consent. This study was approved by the Committee of Ethics of the University of 
Tsukuba. The subjects for case-control study were classified according to AD alone, 
elevated total serum IgE level (>1000 IU/L), and early onset (< 2 years of age). Among 
376 patients with AD, the number of patients with AD alone (i.e., AD patients without 
another atopic disease such as asthma and rhinitis) was 75 (20%). The number with an 
elevated total serum IgE was 212 (56%), and the number with early onset was 112 
(30%).  
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Genotyping  
Genomic DNA was extracted from peripheral blood leukocytes or oral brushed cells 
using standard protocol. R501X and 2282del4 were genotyped by restriction enzyme 
digestion of polymerase chain reaction (PCR) products amplified from DNAs of 96 
unrelated Japanese AD patients. The R501X and 2282del4 variants were PCR 
amplified with the following primer sequences, 5'-CTGGAGGAAGACAAGGATCG 
-3' and 5'-TTGTCTGCTTGCACTTCTGG -3' for the R501X and 
5'-ATCAGGCACTCGTCACACAC-3' and 5'-AGTGCCTGGAGTTGTCTCGT-3' for 
2282del4. PCR products were digested with NlaIII for R501X and DraIII for 2282del4 
at 37°C for 16 h. Digested PCR fragments were subjected to agarose gel 
electrophoresis and visualized by ethidium bromide staining and ultraviolet 
transillumination. Expected product sizes for R501 were 213 base pairs (bp) and 32 bp 
and for X501 allele were 177 bp, 36 bp, and 32 bp. Expected product sizes for the 
wild-type allele of 2282del4 were 458 bp, and for the deletion allele were 240 bp and 
214 bp. 3321delA was genotyped with sizing of a fluorescently labeled PCR fragment 
on an Applied Biosystems 3100 DNA Sequencer (Foster City, CA) as described 
previously (Nomura et al. 2007). Genotype information for the FLG region in Asian 
populations (Japanese and Chinese) was downloaded from the HapMap database 
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(http://www.hapmap.org/cgi-perl/gbrowse/hapmap_B36/), and tag SNPs were selected 
with Tagger software (de Bakker et al. 2005) implemented in Haploview software 
(Barrett et al. 2005) with an r2 threshold of 0.8 and allele frequencies of 0.05. Tag SNPs 
(rs11582620, rs11586114, rs1933064, rs2065958, rs3814299, rs12730241) were 
genotyped with TaqMan Assay-on-DemandTM SNP Typing Systems (Applied 
Biosystems). S2554X was genotyped on a TaqMan Assay-by-Design system for SNP 
genotyping (Applied Biosystems), with the following primer sequences: forward, 
5'-CGGCTCCAGGCACTCA-3', reverse, 5'-ATCCCCAGTTCCTGCTTGTC-3' 
reporter 1 (VIC), 5'-CCCCTCTGATTGTC-3' and reporter 2 (FAM), 
5'-CCCCTCTCATTGTC-3'. The genotyping accuracy was confirmed based on the 
direct sequences of samples obtained from carriers and noncarriers of the S2554X null 
mutation.  
 
Statistical analysis  
Transmission disequilibrium test (TDT) and pedigree disequilibrium test (PDT) were 
performed with the unphased program 
(http//www.mrc-bsu.cam.ac.uk/personal/frank/software.unphased/). Linkage 
disequilibrium (LD) between SNPs, as expressed by D’, was calculated with 
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Haploview software (Barrett et al. 2005). The significance of differences in the allele 
frequencies between case and control groups in case-control comparisons was 
determined by χ2 test. To combine the family and case-control data, control alleles in 
AD families were constructed as non-transmitted parental allele, and case alleles as 
transmitted parental alleles as described by Kirov et al. (Kirov et al. 1999).  
 
Results  
The X501 and 2282del4 alleles were not identified in 96 independent Japanese patients 
with AD. The allele frequencies for all SNPs in the parents in AD families and in 
controls did not deviate from Hardy-Weinberg equilibrium predictions (P > 0.05).  
TDT revealed that the minor alleles of rs2065958 and rs12730241 were 
overtransmitted to AD-affected offspring (P < 0.05, Table 1). However, these results 
were not replicated in the AD case-control study (Table 2). In the AD case-control 
study, we genotyped two non-synonymous SNPs, rs2065958 and rs3814299, because 
rs12730241 is in nearly complete linkage disequilibrium with rs2065958 (r2= 0.95). 
The null allele of S2554X tended to be overtransmitted to AD-affected offspring, 
though the P value did not reach statistical significance. In the case-control 
comparison, the null allele of S2554X was associated statistically significantly with AD 
(Table 2). S2554X was also associated with high IgE levels and the phenotype of 
patients with AD alone. Five percent of patients with the phenotype of patients with 
AD alone carried the S2554X null mutation, whereas only 1% of healthy control 
subjects had the null mutation (P = 2.4×10-5). Three percent of AD patients and 4% of 
those with the phenotype of patients with AD alone carried the 3321delA allele, 
whereas 1% of healthy control subjects had the null mutation. However, this difference 
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was not statistically significant (P > 0.05). Association was observed between 
3321delA and the high-IgE phenotype (P = 0.0036). Combined null mutation carriers 
(subjects carrying either X2554 or 3321delA alleles) were observed more in patients 
with the AD and high-IgE phenotypes than in control subjects. The most significant 
association was observed for the phenotype of patients with AD alone (7 of 67 patients, 
carrier frequency 9.5 %, P = 4.2×10-5). Subjects with compound heterozygous null 
mutations were not observed in our family or case-control samples.  
To combine the TDT and case-control data, the proband of each family was 
selected, and an artificially constructed case population consisting of parental alleles 
transmitted to the affected child and a control population of nontransmitted alleles in 
the AD family trios were determined (Kirov et al. 1999), and these “cases” and 
“controls” in the family trios were combined with the genotype data (Table 3). The 
combined P value was significant for the S2554X polymorphism and null mutations of 
FLG (P = 0.0001), whereas rs2065958 and rs12730241were not associated with 
development of AD. 
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Discussion  
 In the present study, we found that the null allele of S2554X was associated 
with development of AD, confirming previous studies showing that FLG null 
mutations are associated with AD (Nomura et al. 2007). In the present study, 1% of 
healthy subjects without any allergic diseases carried FLG null mutations, whereas no 
control subjects carried the null mutations in a previous study (Nomura et al. 2007). 
Allele frequency of the FLG null mutations in the AD patients were similar to those 
reported previously (Nomura et al. 2007). The null alleles of R501X and 2282del4 
were not detected in 96 Japanese AD subjects.  
FLG is thought to be one of the most important factors in skin barrier 
function. In children, dry skin is often the earliest sign of AD. Impairment of epidermal 
barrier function is a clinical hallmark of AD. Microarray analysis revealed decreased 
expression of FLG mRNA in active atopic skin (Sugiura et al. 2005). These findings 
suggest that dysfunction of FLG is an important factor in the development of AD. In the 
present study, the most significant effect of FLG null mutations was observed in the 
phenotype of patients with AD alone. AD patients often suffer from other atopic 
diseases such as asthma and allergic rhinitis, and patients with multiple atopic diseases 
exhibit increased levels of IgE against allergens. AD patients suffering from other 
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atopic diseases are more likely to exhibit allergic skin inflammation, which leads to the 
development of AD. In contrast, since FLG plays an important role in the skin barrier 
function, the skin may be fragile in carriers of the FLG null allele regardless of the 
atopic status of these individuals, and this may result in the development of AD. 
Therefore, subjects with the phenotype of AD alone are more likely to carry the FLG 
null allele than those with the phenotype of AD along with other atopic diseases.  
The study by Palmer et al. (2006)was the first to show that FLG null 
mutations are associated with AD in Caucasian populations. A number of studies have 
been conducted to replicate the original findings, and some have confirmed and others 
refuted the association of FLG with AD (Marenholz et al. 2006; Ruether et al. 2006; 
Weidinger et al. 2006; Barker et al. 2007; Morar et al. 2007; Stemmler et al. 2007; 
Weidinger et al. 2007). To examine the association of common FLG variants with 
development of AD, we performed tag SNP analysis of Japanese AD families and 
case-control subjects. Two SNPs, including one nonsynonymous mutation, were 
associated with AD by PDT analysis, but this finding was not confirmed in the 
case-control subjects. The statistical power of the case-control study for these SNPs 
was more than 80% at the alpha level of 0.05 if the relative risk for AD in those 
persons carrying a putative risk allele is 1.5 compared with that in persons without the 
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allele. Therefore, our number of case-control samples is sufficient to detect alleles 
confirming moderate risk, but may not be sufficient to detect alleles with weak risk.  
 The results of our family-based association study of S2554X did not reach 
statistical significance, however the null allele of S2554X tended to be overtransmitted 
to affected offspring in our Japanese AD families. In the case-control comparison, 
X2554 was significantly associated with development of AD, and the combined P 
value for the family and case-control data was significant. Because of the low allele 
frequencies of the null alleles in FLG, failure to find an association in the family 
samples is due to low statistical power. The other null allele, 3321delA, was not 
associated with AD. The allele frequency of the 3321delA is very low, 2.7% in AD 
patients and 1.3 % in control. The statistical power in the pedigree samples was less 
than 0.1 at the alpha level of 0.05 if the relative risk for AD in those persons carrying a 
putative risk allele is 2.0 compared with that in persons without the allele. In the 
case-control study, five hundred and sixty-seven cases will be required to achieve 
statistical power of 0.8 at the alpha level of 0.05 if the relative risk for AD in those 
persons carrying a putative risk allele is 2.0 compared with that in persons without the 
allele. Therefore, our sample size is not enough to assess the genotypic relative risk less 
than 2. However, combined analysis of the FLG 3321delA and S2554X null mutations 
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showed significant association with AD. R501X and 2282del4 were the first null 
mutations reported to be associated with AD in a European population (Irvine 2007), 
and a subsequent study identified three additional null alleles of FLG (R2447X, 
S3247X, 3702delG) associated with development of AD (Sandilands et al. 2007). These 
three null mutations were not found in an Asian population (Sandilands et al. 2007), 
whereas the3321delA and S2554X null alleles were not found in a European 
population (Sandilands et al. 2007). Our present tag SNP analysis included common 
missense mutations (D3105Y and L3970S), but the results were not consistent across 
the family and case-control data. In the present study, FLG null mutations were also 
associated with high IgE levels. Allergens can penetrate through the skin, leading to 
allergic sensitization in susceptible individuals. Dysfunction of the skin barrier may 
accelerate allergen penetration, and therefore, loss of FLG function can contribute to 
allergic sensitization and the high-IgE phenotype.  
  In conclusion, FLG null alleles, not common variants, are associated with 
development of AD and high IgE levels in the Japanese, confirming the importance of 
null mutations in FLG for disease onset and allergic sensitization in AD patients.  
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Table1.   TDT and PDT analysis of the FLG polymorphisms in the Japanese AD families  
 
Polymorphism  SNP  Allele  Allele frequency   Ta NTb  TDT P value  PDT P value  
rs11582620  A/G  A  0.89  41  26  0.066  0.059  
rs11586114  A/G  G  0.55  90  78  0.35  0.11  
rs1933064  A/G  A  0.85  44  35  0.31  0.24  
rs2065958(D3105Y)  A/C  C  0.36  69  92  0.069  0.038  
rs3814299(L3970S)  A/G  A  0.63  95  70  0.24  0.38  
rs12730241  A/G  G  0.057 21  14  0.051  0.021  
3321delA  A/- del  0.014 4  4  1  1  
S2554X  C/G  G  0.021 10  4  0.11  0.16  
 
aT: Number of alleles transmitted to affected children  
bNT: Number of alleles not transmitted to affected children
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Table 2.   Case-control study for AD in FLG polymorphisms  
Polymorphism  Populationa Genotype count (frequency%)  Genotypic Pb Odds ratio (95% CI)c Allelic Pb
  C/C  C/A  A/A     
rs2065958  AD 58 (15.6)  156 (41.9)  158 (42.5)  0.94  1.0 (0.8-1.2)  0.84  
 only AD  9 (12.3)  25 (34.3)  39 (53.4)  0.14  0.6 (0.4-1.0)  0.068  
 IgE>1000IU/L  30 (14.2)  90 (42.9)  90 (42.9)  0.89  1.0 (0.7-1.3)  0.62  
 early onset  12 (10.7)  57 (50.9)  43 (38.4)  0.20  1.1 (0.8-1.7)  0.81  
 Controls  142 (15.5)  393 (43.0)  380 (41.5)     
  A/A  A/G  G/G     
rs3814299  AD 2 (0.5)  52 (13.8)  322 (85.7)  0.64  1.1 (0.8-1.6)  0.54  
 AD alone  0 (0)  12 (16.0)  63 (84.0)  0.46  1.3 (0.7-2.5)  0.57  
 IgE>1000IU/L  1 (0.5)  34 (16.1)  176 (83.4)  0.26  1.4 (0.9-2.0)  0.21  
 early onset  1 (0.9)  14 (12.5)  97 (86.6)  0.98  1.1 (0.6-1.9)  0.84  
 Controls  7 (0.8)  111 (12.0)  804 (87.2)     
  A/A  A/ -  - / -    
3321delA  AD 356 (97.3)  10 (2.7)  0 (0)  0.077  2.1 (0.9-4.9)  0.077  
 AD alone  71 (95.9)  3 (4.1)  0 (0)  0.064  3.2 (0.9-11.5)  0.064  
 IgE>1000IU/L  198 (95.6)  9 (4.4)  0 (0)  0.0038  3.4 (1.4-8.2)  0.0036  
 early onset  103 (97.2)  3 (2.8)  0 (0)  0.22  2.2 (0.6-7.9)  0.22  
 Controls  902 (98.7)  12 (1.3)  0 (0)     
  C/C  C/G  G/G     
S2554X  AD 365 (97.3)  10 (2.7)  0 (0)  0.0012  5.0 (1.7-14.8)  0.0012  
 AD alone  71 (94.7)  4 (5.3)  0 (0)  0.000024  10.3 (2.7-39.4)  0.000024 
 IgE>1000IU/L  207 (97.6)  5 (2.3)  0 (0)  0.011  4.4 (1.3-15.5)  0.011  
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 early onset  110 (98.2)  2 (1.8)  0 (0)  0.13  3.3 (0.6-17.4)  0.13  
 Controls  918 (99.5)  5 (0.5)  0 (0)     
combined   wild allele / wild allele wild / at least one null allele null  / null     
(3321delA and S2554X)  AD 355 (64.7)  20 (5.3)  0 (0)  0.00073  3.0 (1.5-5.8)  0.00067
 AD alone  67 (90.5)  7 (9.5)  0 (0)  0.000047  5.5 (2.2-13.8)  0.000042
 IgE>1000IU/L  198 (93.4)  14 (6.6)  0 (0)  0.00015  3.7 (1.8-7.7)  0.00014
 early onset  101 (95.3)  5 (4.7)  0 (0)  0.054  2.6 (1.0-7.3)  0.056  
 Controls  900 (98.1)  17 (1.9)  0 (0)     
 
a AD alone; AD patients without other atopic disease.  Early onset; patients whose disease onset was younger than 2 years old.  
b Genotypic P and alleleic P values were calculated with χ2 test in comparison with genotype and allele counts in controls, respectively.  
c Odds ratio for the wild type homozygote versus minor allele heterozygote and minor allele homozygote. CI, confidence interval.  
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Table 3.   Combined P values of FLG polymorphisms in families and case-control study   
Polymorphism  Genotype count (frequency)   Genotypic Pa  Odds ratio (95% CI)b  Allelic Pa  
  C/C  C/A  A/A     
rs2065958  AD  65 (13.8) 202 (43.0)  203 (43.2)  0.54  0.92 (0.7-1.1)  0.28  
 Controls  161 (15.9)  437 (43.0)  417 (41.1)     
  A/A  A/G  G/G     
rs12730241  AD  4 (0.8)  60 (12.6) 412 (86.6)  0.91  1.1 (0.8-1.5)  0.69  
 Controls  7 (0.7)  124 (12.1)  892 (87.2)     
  A/A  A/ -  - / -     
3323delA  AD  454 (97.4)  12 (2.6)  0 (0)  0.14  1.8 (0.8-3.8)  0.14  
 Controls  999 (98.5)  15 (1.5)  0 (0)     
  C/C  C/G  G/G     
S2554X  AD  459 (97.6)  16 (3.4)  0 (0)  0.000091 5.0 (2.1-12.3)  0.0001  
 Controls  1010 (99.3)  7 (0.7)  0 (0)     
combined   wild  / wild  wild / null  null / null     
(3321delA and S2554X)  AD  438 (94.0)  28 (6.0)  0 (0)  0.00015  2.9 (1.6-5.1)  0.00017  
 Controls  992 (97.8)  22 (2.2)  0 (0)     
 
aGenotypic P and alleleic P values were calculated with χ2 test in comparison with genotype and allele counts in controls, respectively.  
b Odds ratio for the wild type homozygote versus minor allele heterozygote and minor allele homozygote. CI, confidence interval.  
 
  
